These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32276580)

  • 1. BREED based de novo hybridization approach: generating novel T790M/C797S-EGFR tyrosine kinase inhibitors to overcome the problem of mutation and resistance in non small cell lung cancer (NSCLC).
    Patel HM; Shaikh M; Ahmad I; Lokwani D; Surana SJ
    J Biomol Struct Dyn; 2021 May; 39(8):2838-2856. PubMed ID: 32276580
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Patel HM; Ahmad I; Pawara R; Shaikh M; Surana S
    J Biomol Struct Dyn; 2021 Mar; 39(4):1491-1505. PubMed ID: 32102624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p38α MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor.
    Ahmad I; Shaikh M; Surana S; Ghosh A; Patel H
    J Biomol Struct Dyn; 2022 Apr; 40(7):3046-3059. PubMed ID: 33174519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR
    Park HR; Kim TM; Lee Y; Kim S; Park S; Ju YS; Kim M; Keam B; Jeon YK; Kim DW; Heo DS
    J Thorac Oncol; 2021 Nov; 16(11):1859-1871. PubMed ID: 34242789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer.
    Akazawa Y; Saito Y; Yoshikawa T; Saito K; Nosaka K; Shimomura M; Mizuno S; Nakamoto Y; Nakatsura T
    Cancer Sci; 2020 Aug; 111(8):2736-2746. PubMed ID: 32391625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction and molecular dynamics simulation study of Osimertinib (AstraZeneca 9291) anticancer drug with the EGFR kinase domain in native protein and mutated L844V and C797S.
    Assadollahi V; Rashidieh B; Alasvand M; Abdolahi A; Lopez JA
    J Cell Biochem; 2019 Aug; 120(8):13046-13055. PubMed ID: 30916819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational Computational Design of Fourth-Generation EGFR Inhibitors to Combat Drug-Resistant Non-Small Cell Lung Cancer.
    Park H; Jung HY; Kim K; Kim M; Hong S
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33297461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer.
    Wang S; Tsui ST; Liu C; Song Y; Liu D
    J Hematol Oncol; 2016 Jul; 9(1):59. PubMed ID: 27448564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to Brigatinib Targeted Therapy in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 19 Deletion, T790M, and cis-C797S Triple Mutations: A Case Report.
    Chen ZW; Lin G; Shih HJ; Wu CE
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer.
    Lim SM; Fujino T; Kim C; Lee G; Lee YH; Kim DW; Ahn JS; Mitsudomi T; Jin T; Lee SY
    Clin Cancer Res; 2023 Aug; 29(16):3004-3016. PubMed ID: 37249619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition.
    Patel H; Pawara R; Surana S
    Comput Biol Chem; 2018 Jun; 74():167-189. PubMed ID: 29627693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Novel Fourth-Generation EGFR Inhibitors to Overcome C797S-Mediated Resistance.
    Zhu Y; Ye X; Shen H; Li J; Cai Z; Min W; Hou Y; Dong H; Wu Y; Wang L; Wang X; Xiao Y; Yang P
    J Med Chem; 2023 Nov; 66(21):14633-14652. PubMed ID: 37885208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy.
    Wang Y; Yang N; Zhang Y; Li Li ; Han R; Zhu M; Feng M; Chen H; Lizaso A; Qin T; Liu X; He Y
    J Thorac Oncol; 2020 Aug; 15(8):1369-1375. PubMed ID: 32353596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting EGFR
    Lu X; Yu L; Zhang Z; Ren X; Smaill JB; Ding K
    Med Res Rev; 2018 Sep; 38(5):1550-1581. PubMed ID: 29377179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and optimization of 4-anilinoquinazoline derivatives spanning ATP binding site and allosteric site as effective EGFR-C797S inhibitors.
    Dou D; Wang J; Qiao Y; Wumaier G; Sha W; Li W; Mei W; Yang T; Zhang C; He H; Wang C; Chu L; Sun B; Su R; Ma X; Gong M; Xie L; Jiang W; Diao Y; Zhu L; Zhao Z; Chen Z; Xu Y; Li S; Li H
    Eur J Med Chem; 2022 Dec; 244():114856. PubMed ID: 36279692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations.
    Du Y; Chen Y; Wang Y; Chen J; Lu X; Zhang L; Li Y; Wang Z; Ye G; Zhang G
    Mol Cancer Ther; 2022 Jul; 21(7):1060-1066. PubMed ID: 35499406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a novel nitroflavone-based scaffold for designing mutant-selective EGFR tyrosine kinase inhibitors targeting T790M and C797S resistance in advanced NSCLC.
    Cristina M; Emiliano L; Leonardo S; Giulia S; Roberta G; Adolfo A; Marta SS; Paola S; Samuele R; Pierluigi S; Massimo M; Giovanna M
    Bioorg Chem; 2022 Dec; 129():106219. PubMed ID: 36308853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of molecular mechanism leading to gefitinib and osimertinib resistance against EGFR tyrosine kinase: molecular dynamics and binding free energy calculation.
    Singh A; Mishra A
    J Biomol Struct Dyn; 2023 Jul; 41(10):4534-4548. PubMed ID: 35510318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.
    Zhang YC; Chen ZH; Zhang XC; Xu CR; Yan HH; Xie Z; Chuai SK; Ye JY; Han-Zhang H; Zhang Z; Bai XY; Su J; Gan B; Yang JJ; Li WF; Tang W; Luo FR; Xu X; Wu YL; Zhou Q
    EBioMedicine; 2019 May; 43():180-187. PubMed ID: 31027916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation.
    Kashima K; Kawauchi H; Tanimura H; Tachibana Y; Chiba T; Torizawa T; Sakamoto H
    Mol Cancer Ther; 2020 Nov; 19(11):2288-2297. PubMed ID: 32943545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.